Melatonin and the Metabolic Syndrome

NCT01038921 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2015-02-27

Study results available
· View outcomes & findings →

Summary

This trial seeks to compare the effects of melatonin supplementation versus placebo in subjects with the metabolic syndrome.

Conditions

  • Metabolic Syndrome

Interventions

DRUG

Melatonin

8 mg dose of Melatonin

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Michael H Kutner, PhD · Emory University

  • Abinav Goyal, M.D. · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
30 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2012-06-30
Completion
2013-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038921 on ClinicalTrials.gov